Cyclopharm Limited (CYC) Fair Value & Analysis
Healthcare · AU · Market cap A$75.4M
Fair value as of: Jul 17, 2026
From 1 valuation models · updated 24 days ago
Share price +8.6% over the past month.
Below-average quality, and screening another 86% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (A$0.0900). The favourable scenario is already priced in.
- Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range A$0.4600 – A$2.90 · fair‑value band A$0.0500 – A$0.0900 · the A$0.5700 price screens above the A$0.0800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Cyclopharm Limited (CYC) currently trades at A$0.5700, while our model-based Fair Value estimate is A$0.0800, implying the stock looks roughly 86.0% overvalued today. The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Cyclopharm Limited generated revenue of A$32.3M at a net margin of -53.3%. Revenue grew 10.5% year over year. It earns a return on equity of -49.3%. Net debt stands at A$8.3M. Fundamentals as of Jul 17, 2026
Our scenario range runs from A$0.0500 (bear case) to A$0.0900 (bull case); at A$0.5700, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 56% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -86%, CYC screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when CYC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 34 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions.
Full company description
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cyclopharm Limited reported revenue of A$32.3M in FY2025 versus A$17.7M in FY2021, a compound +16.2%/yr. Reported net income was −A$17.2M in FY2025.
CYC screens 86% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare Cyclopharm Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cyclopharm Limited (CYC) overvalued or undervalued?
What is the fair value of CYC?
What is the quality score of CYC?
What is the revenue of Cyclopharm Limited (CYC)?
What is the net profit margin of CYC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cyclopharm Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.